JANX
Janux Therapeutics, Inc.NASDAQHealthcare$14.84+2.27%ClosedMarket Cap: $902.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.97
P/S
50.83
EV/EBITDA
-6.69
DCF Value
$-2.74
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
47.2%
Operating Margin
-881.8%
Net Margin
-635.5%
ROE
-11.5%
ROA
-11.3%
ROIC
-16.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.9M | -13.5% | $-42.4M | $-31.9M | $-0.51 | — |
| FY 2025 | $10.0M | 79.7% | $-157.7M | $-113.6M | $-1.83 | — |
| Q3 2025 | $10.0M | 95.0% | $-35.3M | $-24.3M | $-0.39 | — |
| Q2 2025 | $0.00 | NaN% | $-45.1M | $-33.9M | $-0.55 | — |
| Q1 2025 | $0.00 | NaN% | $-34.9M | $-23.5M | $-0.38 | — |
| Q4 2024 | $0.00 | NaN% | $-29.0M | $-20.2M | $-0.36 | — |
| FY 2024 | $10.6M | 80.5% | $-98.8M | $-69.0M | $-1.28 | — |
| Q3 2024 | $439.0K | 100.0% | $-35.8M | $-28.1M | $-0.51 | — |
| Q2 2024 | $8.9M | 94.3% | $-13.8M | $-6.0M | $-0.11 | — |
| Q1 2024 | $1.3M | 57.5% | $-20.2M | $-14.8M | $-0.30 | — |
| Q4 2023 | $2.5M | 78.4% | $-16.1M | $-11.8M | $-0.25 | — |
| FY 2023 | $8.1M | 75.8% | $-73.0M | $-58.3M | $-1.32 | — |